Day: January 10, 2022

TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio

Medically Home Announces a $110 Million Strategic Investment Led by Baxter International Inc., Global Medical Response and Cardinal Health to Advance Leadership in Hospital-Level Patient Care at Home

error: Content is protected !!